Carl Anthony Blau

US Patent:

7754202, Jul 13, 2010

Filed:

Jan 7, 1999

Appl. No.:

09/582916

Inventors:

Carl Anthony Blau - Seattle WA, US
David M. Spencer - Houston TX, US

Assignee:

Stanford University - Palo Alto CA
University of Washington - Seattle WA

International Classification:

A61K 48/00
C12N 5/00
C12N 15/63

US Classification:

424 9321, 514 44 R, 435325, 4353201, 435455

Abstract:

This invention involves methods and materials for conferring a direct proliferative advantage on a genetically modified subpopulation of cells. Selection is then accomplished by exerting a positive selective stimulus on the engineered cells rather than a negative pressure on nonengineered cells.

US Patent:

20050238628, Oct 27, 2005

Filed:

Apr 7, 2005

Appl. No.:

11/100817

Inventors:

Carl Blau - Seattle WA, US

International Classification:

A61K048/00

US Classification:

424093210

Abstract:

The present invention relates to methods and compositions for treating cancer and related diseases.

US Patent:

20100297639, Nov 25, 2010

Filed:

Oct 8, 2008

Appl. No.:

12/682105

Inventors:

Christopher P. Miller - Seattle WA, US
Carl Anthony Blau - Seattle WA, US
Michael Henke - Freiberg, DE

Assignee:

UNIVERSITY OF WASHINGTON through its Center for Commercialization - Seattle WA

International Classification:

C12Q 1/68
G01N 33/53
G01N 33/574

US Classification:

435 6, 435 792, 435 723

Abstract:

The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin.

US Patent:

20210285933, Sep 16, 2021

Filed:

Jul 3, 2019

Appl. No.:

17/257945

Inventors:

- Seattle WA, US
Su-In LEE - Seattle WA, US
Carl BLAU - Seattle WA, US
Vivian OEHLER - Seattle WA, US
Timothy MARTINS - Seattle WA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

G01N 33/50

Abstract:

Described herein are functional cell assays and methods for selecting a personalized anti-cancer treatment regimen that can improve treatment of cancer in a subject, identify resistance of the subject's cancer to one or more anti-cancer agents and/or validate the current drug treatment strategy.